









Markets
/
Stocks
/
nasdaq-mtnb
/

Matinas BioPharma Holdings Inc

MTNB

1.270USD

-0.070-5.22%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

6.46MMarket Cap

LossP/E TTM



Matinas BioPharma Holdings Inc

1.270

-0.070-5.22%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Matinas BioPharma Holdings Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Matinas BioPharma Holdings Inc's Score

Industry at a Glance

Industry Ranking

224 / 407

Overall Ranking

442 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Matinas BioPharma Holdings Inc Highlights

StrengthsRisks

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -0.33, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 289.20K shares, decreasing 80.64% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.22.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.88, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.88

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.90

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.70

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Matinas BioPharma Holdings Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 8.70, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.33, which is -100.00% below the recent high of 0.00 and -2201.00% above the recent low of -7.56.

Score

Industry at a Glance

Previous score

8.70

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 224/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 4.41, which is lower than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 1.71 and the support level at 1.04, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.90

Change

0.51

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.078

Sell

RSI(14)

30.252

Neutral

STOCH(KDJ)(9,3,3)

6.245

Oversold

ATR(14)

0.119

Low Volatility

CCI(14)

-120.148

Sell

Williams %R

98.413

Oversold

TRIX(12,20)

-1.114

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

1.338

Sell

MA10

1.439

Sell

MA20

1.609

Sell

MA50

1.747

Sell

MA100

1.437

Sell

MA200

1.037

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-04

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Lazar (David Elliot)

545.00K

Stern (Adam K.)

210.69K

Sanitam Partners LLC

210.69K

111 Equity Group LLC

183.64K

-25.95%

The Vanguard Group, Inc.

Star Investors

59.73K

Geode Capital Management, L.L.C.

55.49K

+18.73%

BlackRock Institutional Trust Company, N.A.

49.65K

Sargent Investment Group, LLC

35.62K

-14.78%

Holos Integrated Wealth LLC

32.48K

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 1.41, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.29. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.